Given the chronic nature of endometriosis, the adverse effects of GnRH agonists preclude its long-term use for this indication, and there is insufficient evidence of the benefits of using lower GnRH agonist doses (i.e., ‘draw-back’ therapy) [51,83]. Here, GNRH1 is linked to endometriosis.